Illinois Retina Associates

1 marketed · 1 in Phase 3

Quick facts

Marketed products

Ranibizumab plus Photodynamic therapy · Ophthalmology
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue.

Phase 3 pipeline

proparacaine HCL 0.5%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: